A dual acting compound releasing nitric oxide (NO) and ibuprofen, NCX 320, shows significant therapeutic effects in a mouse model of muscular dystrophy  by Sciorati, Clara et al.
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A  resolutive  therapy  for muscular  dystrophies,  a heterogeneous  group  of  genetic  diseases  leading  to
muscular degeneration  and  in  the  severe  forms  to death,  is  still  lacking.  Since  inﬂammation  and  defects
in  nitric  oxide  generation  are  recognized  key  pathogenic  events  in  muscular  dystrophy,  we  have analysed
the effects  of  a derivative  of  ibuprofen,  NCX  320, belonging  to the  class  of  cyclooxygenase  inhibiting  nitric
oxide  donator  (CINOD),  in  the  -sarcoglycan  null  mice,  a  severe  mouse  model  of  dystrophy.  NCX  320  was
administered  daily  in  the  diet  for  8 months  starting  1 month  from  weaning.  Muscle  functional  recovery
was  evaluated  by  free  wheel  and  treadmill  tests  at  8 months.  Serum  creatine  kinase  activity,  as  well
as the  number  of  diaphragm  inﬂammatory  inﬁltrates  and  necrotic  ﬁbres,  was  measured  as  indexes  of
skeletal muscle  damage.  Muscle  regeneration  was  evaluated  in diaphragm  and  tibialis  anterior  muscles,
measuring  the  numbers  of  centronucleated  ﬁbres  and  of  myogenic  precursor  cells.  NCX  320  mitigated
muscle  damage,  reducing  signiﬁcantly  serum  creatine  kinase  activity,  the  number  of  necrotic  ﬁbres  and
inﬂammatory  inﬁltrates.  Moreover,  NCX  320  stimulated  muscle  regeneration  increasing  signiﬁcantly  the
number  of  myogenic  precursor  cells  and  regenerating  ﬁbres.  All  these  effects  concurred  in  inducing  a
signiﬁcant  improvement  of  muscle  function,  as assessed  by  both  free  wheel  and  treadmill  tests.  These
results  describe  the  properties  of  a new  compound  incorporating  nitric  oxide  donation  together  with
anti-inﬂammatory  properties,  showing  that  it is  effective  in slowing  muscle  dystrophy  progression  long
term.  Of  importance,  this  new  compound  deserves  speciﬁc  attention  for its  potential  in  the  therapy  of
muscular  dystrophy  given  that  ibuprofen  is well  tolerated  in  paediatric  patients  and  with  a  proﬁle  of
safety  that  makes  it suitable  for chronic  treatment  such  as  the  one  required  in  muscular  dystrophies.. IntroductionNitric oxide (NO) is involved in many mechanisms responsi-
le for preserving muscle function [1] including both pre-synaptic
Abbreviations: NO, nitric oxide; DMD, Duchenne muscular dystrophy; NCX
20, 4-(nitrooxy)butyl 2-(4-isobutylphenyl)propanoate; CINOD, cyclooxygenase
nhibiting nitric oxide donator; nNOS, neuronal nitric oxide synthase; LPS,
ipopolysaccharide from Escherichia coli; PGE2, prostaglandin E2; IFN, interferon-;
OX-1, cyclooxygenase 1; COX-2, cyclooxygenase 2; ODQ, 1H-[1,2,4]oxadiazolo[4,3-
]quinoxalin-1-one; cGMP, cyclic guanosine monophosphate; CK, creatine kinase;
-SG, -sarcoglycan; mdx, muscle dystrophin-deﬁcient mice.
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tive Medicine, Via Olgettina 58, 20132, Milan, Italy, Tel.: +39 0226434814;
ax: +39 0226434813.
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Open access under CC BY-NC-ND license.© 2011 Elsevier Ltd. 
and post-synaptic neuromuscular transmission, energy supply and
mitochondrial biogenesis [1–4]. In addition, NO regulates repair of
the damaged muscle via speciﬁc actions on satellite cells, mononu-
clear progenitor cells found in mature muscle and located between
the basal lamina and sarcolemma which are normally quiescent,
but they can be activated in response to muscle injury [5–8].
Alteration in the amount and localisation of NO synthesis has
been implicated in the pathophysiology of skeletal muscle dys-
trophies. These genetic degenerative diseases of the muscle are
due to defects in muscle proteins, leading to structure alteration
and continuous damage of ﬁbres during contraction [9].  Duchenne
muscular dystrophy (DMD) is the most severe form, with a paedi-
Open access under CC BY-NC-ND license.atric onset and often leading to rapid paralysis and a premature
death, usually by respiratory and/or cardiac failure before 20th
year of age [9].  In DMD, as well as in the mouse models of muscu-
lar dystrophies, mdx  or -sarcoglycan (SG) null mouse, the splice
gical Research 64 (2011) 210– 217 211
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ariant of neuronal nitric oxide synthase (nNOS)  is absent from
he sarcolemma, and relocated to the cytosol, with total muscle
OS activity being thus reduced [10]. Overexpression of nNOS in
he mdx  mouse was shown to yield substantial recovery of muscle
tructure [11].
Histological analyses of dystrophic skeletal muscle in human
nd in mice show that skeletal muscle myoﬁbres are progressively
ubstituted by connective and adipose tissue [9].  This continuous
bre damage is counteracted, at least initially, by sustained pro-
iferation and activation of satellite cells leading to regeneration
f ﬁbres; in later phases depletion of the pool of myogenic pre-
ursors, due to the repeated cycles of activation and proliferation,
eads to signiﬁcant decrease of the muscle repair capacity [12,13].
nhanced ﬁbres destruction is also due to the extensive inﬂam-
atory response occurring within the muscle, which contributes
igniﬁcantly to progression of muscular dystrophies [14]. Indeed,
NA microarray and biochemical data show that inﬂammatory
ediators/effectors dominate the expression proﬁle of muscles
rom the mdx  mouse model of dystrophy [15,16].
A variety of pharmacological and genetic approaches, aimed at
egulating NO supply to the muscle, have been used to ameliorate
he disease progression in both the -SG-null and the mdx  mouse
odels [6,11,17–23].
We  have recently reported that combining NO donation with
 non steroidal anti-inﬂammatory agent leads to a recovery of
uscle function which is both signiﬁcant and persistent [18,24].
peciﬁcally, chronic administration of the NO-donating ﬂurbipro-
en HCT 1026, belonging to the CINOD (cyclooxygenase-inhibiting
itric oxide (NO)-donator) class [25], exerted signiﬁcant thera-
eutic effects in two different mouse models of dystrophy [18].
CT 1026 signiﬁcantly slowed disease progression, maintaining the
unctional capacity of muscles by reducing necrosis and inﬂam-
ation, and preserving the regenerative potential in both the
-SG-null and the mdx  mouse models. Since ﬂurbiprofen is a potent
nti-inﬂammatory agent associated with marked gastro-intestinal
ide effects and it is not approved for use in paediatric patients, we
ave focused our attention on a chemically related drug, ibuprofen,
hich is more widely used also in paediatric patients because of its
roﬁle of safety [26–29].
In this study we have analysed the long-term efﬁcacy of a deriva-
ive of ibuprofen, namely NCX 320, which targets two mechanisms:
O donation and cyclooxygenase inhibition. We  have deﬁned its
harmacological proﬁle in terms of kinetics of ibuprofen and NO
elease using biochemical and functional assays. We  have then
xamined the therapeutic potential of NCX 320 in the -SG-null
ice, which are characterised by a severe dystrophic phenotype
ith progressive damage and reduced regeneration capacity. NCX
20 induced persistent and signiﬁcant reduction of both ﬁbre dam-
ge and inﬂammation, thus preserving muscle integrity. Moreover,
CX 320 signiﬁcantly increased the myoblast precursor number
nd differentiation capacity, maintaining the long-term regenera-
ion capacity of muscle. The data with the prototype NCX 320 show
hat a dual-acting compound possesses a potential for treatment of
uscular dystrophies.
. Materials and methods
.1. Materials
NCX 320 (Fig. 1), 4-(nitrooxy)butyl 2-(4-isobutylphenyl)
ropanoate, was synthesized at the NicOx Research Institute
Bresso, Milan, Italy). Ibuprofen was obtained from Albemarle Cor-
oration (Baton Rouge, LA, USA). Interferon- (IFN) was from
oche Molecular Biochemicals (Mannheim, Germany). Dulbecco’s
odiﬁed Eagle’s medium (DMEM), foetal calf serum, and peni-Fig. 1. Chemical structure for NCX 320 4-(nitrooxy)butyl 2-(4-
isobutylphenyl)propanoate, synthesized at the NicOx Research Institute (Bresso,
Milan, Italy).
cillin/streptomycin were purchased from Invitrogen (Carlsbad, CA,
USA). PGE2 EIA-kit was purchased from Cayman Chemical (Ann
Arbor, Michigan, USA). The protease inhibitor cocktail was  pur-
chased from Roche (Basel, Switzerland). Elisa kits for cytokines
determinations were purchased from R&D System (Minneapolis,
MN,  USA). Fluorescein isothiocyanate-conjugated CD34 antibody
was  purchased from AbD Serotec (Oxford, UK) and phycoerythrin-
conjugated 7-integrin antibody from MBL  (Woburn, MA,  USA).
All other chemicals were purchased from Sigma–Aldrich (St. Louis,
MO,  USA).
2.2. In vitro proﬁle of NCX 320
2.2.1. Cyclooxygenase activity inhibition
To assess cyclooxygenase (COX)-inhibiting properties of the
compound, COX-1 and COX-2 activities were studied using resting
and LPS/IFN-stimulated RAW 264.7 cells respectively, as previ-
ously described [30]. The experiments were carried out in the
presence of 1 M of each enzyme and porcine liver esterases (1.7
units per sample) were added to facilitate the release of ibuprofen
from NCX 320.
2.2.2. Vasodilating effects
NO-donating activity was  studied in the vascular relaxation
assay in rabbit aorta as previously described [31], Brieﬂy, the
aortic rings were suspended in organ chambers containing
Krebs solution and connected to a force displacement trans-
ducer (Grass FT03) for the measurement of isometric force.
After equilibration, aortic segments were pre-contracted submax-
imally with methoxamine (3 M)  and, after obtaining a stable
tone, a cumulative concentration–response curve of test drugs
(0.01–100 M)  was  established in the absence or presence of
the soluble guanylate cyclase inhibitor, 1H-[1,2,4]oxadiazolo[4,3-
a]quinoxalin-1-one (ODQ; 10 M)  to determine the vasodilating
effects dependent on NO/cyclic guanosine monophosphate (cGMP).
Data were expressed as percent of relaxation and plotted vs con-
centration.
2.3. In vivo efﬁcacy of NCX 320 in ˛-SG mice
2.3.1. Animals and drug treatment
-SG null mice were a kind gift of Dr. K Campbell (Iowa Univer-
sity, Iowa City, IA, USA). Animals were housed in the pathogen-free
facility at the San Raffaele Scientiﬁc Institute (Milano-Italy), and
treated in accordance with the European Community guidelines,
and with the approval of the Institutional Ethical Committee. Mice
(15 animals/group) were treated with 50 mg/kg/die of ibuprofen
or 65 mg/kg/die of NCX 320 (equimolar to ibuprofen) administered
daily into the diet (Mucedola, Milano, Italy) or with the same food
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ithout drug (control group) starting at 1 month of age for up to
 months. Animals were subjected to the following tests: serum
reatine kinase (CK) activity monthly for up to the 3rd month of
reatment (4 months of age), functional tests (free wheel running
nd treadmill) after 8 months of treatment. At the 4th and 8th
onth of treatment mice were sacriﬁced for histological analyses,
ytokine measurements and preparation of primary myoblasts. For
lasma measurements of the steady state concentrations of ibupro-
en, nitrites or nitrates, separate groups of mice (7 mice/group)
ere treated as above for 1 week.
.3.2. Determination of ibuprofen, nitrites and nitrates in plasma
One-week following NCX 320 treatment, plasma was  obtained
rom the heart of animals and centrifuged 13,000 × g at 4 ◦C for
 min  to remove cells. Plasma ibuprofen concentrations were
ssessed using previously published methods [32,33]. The method
as linear from 2.5 to 250 M,  imprecision as well as inaccuracy
as below 10%.
For quantitative NO measurements, prior to the derivatiza-
ion procedure, plasma (100 L) were spiked with the 15N-labeled
itrite and nitrate as internal standards to achieve ﬁnal con-
entrations of 0.2 M for [15N]nitrite and 2 M for [15N]nitrate.
erivatization and quantiﬁcation of nitrite and nitrate was  per-
ormed as described [34].
.3.3. Biochemical analyses and functional tests in dystrophic
uscle
Serum CK levels were measured in blood samples obtained by
ail vein withdrawal using an indirect commercially available col-
rimetric assay (Randox, UK) [17].
Functional muscle activity was measured using both the run-
ing wheel to assess free locomotor activity and the exhaustion
readmill to assess resistance to fatigue [17]. For the running wheel,
hree tests were performed on the same animal allowing 2 days
n between each measure, while the exhaustion treadmill test was
erformed after an appropriate training period and three tests were
erformed on the same animal allowing 1 week in between each
est.
.3.4. Histological analysis
The animals were sacriﬁced by cervical dislocation and
iaphragm muscle was dissected and immediately frozen in liquid
2 cooled isopentane. Haematoxilin–Eosin (H&E) or the Masson
richrome stainings were performed in serial muscle sections fol-
owing manufactures procedures (Bio Optica, Milan Italy). At least
0 random images for each muscle were taken at 10× magniﬁca-
ion with a S100 TV microscope (Carl Zeiss MicroImaging Inc, Iena,
ermany) and analysed using a digitized imaging system (ImageJ
.38× National Institute of Health) for counting necrotic and cen-
ronucleated ﬁbres and for evaluating inﬁltrated inﬂammatory cell
umber. Necrotic cells were identiﬁed by hypereosinophilia, thin-
ing, waviness and eventually presence of many nuclei [35].
.3.5. Cytokine determination in tibialis anterior muscle
Tibialis anterior muscles were isolated from sacriﬁced ani-
als and rapidly homogenized in 20 mM  Tris–HCl, containing
37 mM NaCl, 5 mM ethylenediaminetetraacetic acid and a pro-
ease inhibitor cocktail, pH 8.0, and centrifuged at 3000 rpm for
 min  at 4 ◦C. After protein content determination, equal amounts of
rotein were analysed using commercially available kits according
o manufacturer’s instructions..3.6. Primary myoblast cells isolation and analysis
Primary myoblasts were isolated from quadriceps and gastroc-
emius muscles as previously described [20]. Myoblasts were then
ounted and stained with a ﬂuorescein isothiocyanate-conjugatedesearch 64 (2011) 210– 217
CD34 antibody and a phycoerithrin-conjugated 7-integrin-
antibody according to manufacturer’s protocol. The number of
double positive cells was  measured by ﬂow cytometry analysing
10,000 events for each sample (FACScalibur, Becton Dickinson, San
Jose, CA, USA). Aliquots (1 × 105) of isolated cells were cultured
using matrigel-coated dishes in DMEM supplemented with 10%
foetal calf serum, 3% chick embryo, 100 U/mL penicillin, 100 g/mL
streptomycin, and 50 g/mL gentamycin for 1 week. To induce
myotube formation cells were then cultured for 24 h in differ-
entiation medium (DMEM supplemented with 2% horse serum,
100 U/mL penicillin, and 100 g/mL streptomycin). Cells were lysed
and analysed for differentiation proteins expression by sodium-
dodecylsulfate electrophoresis as described [20].
2.4. Statistical analysis
Results are expressed as the mean ± SEM or median (interquar-
tile range) according to their distribution based on results of the
Kolmogorov–Smirnov normality test. For the parameters with a
normal distribution, the Student’s t-test was used, whereas the
Mann–Whitney test was  used for parameters with non-normal dis-
tribution. A p-value <0.05 was  considered as statistically signiﬁcant.
3. Results
3.1. In vitro proﬁle of NCX 320
3.1.1. NCX 320 inhibits COX-1 and COX-2 activities
To evaluate the anti-inﬂammatory effects of NCX 320, we
investigated its COX inhibitory activity in resting (COX-1) or
LPS/IFN-stimulated (COX-2) RAW 264.7 cells. NCX 320 inhibited
in a concentration-dependent manner the COX-1 and COX-2 activ-
ities (IC50 of 8.1 ± 1.1 and 21.6 ± 1.2 M respectively) similarly to
ibuprofen, which displayed an IC50 of 11.7 ± 1.2 M for COX-1 and
18.2 ± 1.5 M for COX-2 (Fig. 2A). The experiments were carried
out in the presence of porcine liver esterases (1.7 units per sample)
to facilitate the release of ibuprofen from NCX 320.
3.1.2. NCX 320 induces NO-dependent vasodilation
We evaluated whether NCX 320 releases bioac-
tive NO, investigating NO-mediated vasorelaxation on
methoxamine-precontracted rabbit aortic rings. Cumulative
concentration–response curves to NCX 320 evoked concentration-
dependent relaxation with an EC50 of 20.9 ± 3.9 M, achieving
85% relaxation at the highest concentration tested of 100 M
(Fig. 2B). These vasodilating effects depended on the activation
of the NO/cGMP pathway, as they were fully antagonized by
ODQ, a selective soluble guanylate cyclase (sGC) inhibitor (Emax:
22 ± 4%). Under the same conditions, ibuprofen (Emax: 35 ± 1%)
was  completely inactive up to the highest concentration tested
(100 M).
3.2. In vivo efﬁcacy of NCX 320 in ˛-SG mice
3.2.1. NCX 320 releases ibuprofen and NO following oral
administration in ˛-SG null mice
Following 1 week of treatment with NCX 320 incorporated into
the diet (65/mg/kg/die), we assessed the steady state plasma con-
centrations of ibuprofen and of nitrites or nitrates, as product of
NO metabolism. Plasma levels of ibuprofen were 22.0 ± 3.2 g/mL,
a value similar to that found after a paediatric oral dose of
ibuprofen (150–300 mg/day) [36,37].  Nitrites and nitrates levels
were signiﬁcantly (p < 0.05) increased when compared to control
animals (3.80 ± 0.10 M and 39.7 ± 2.1 M,  respectively, for NCX
C. Sciorati et al. / Pharmacological Research 64 (2011) 210– 217 213
Fig. 2. NCX 320 inhibits COX-1 and COX-2 activities in RAW macrophages and induces vascular relaxation in rabbit aorta. (A) Inhibitory proﬁle on COX-1 and COX-2 obtained
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ty  NCX 320 (ﬁlled triangles) or ibuprofen (open squares); the extent of drug-indu
B)  Cumulative-concentration curve to NCX 320 (ﬁlled triangles) and ibuprofen (op
nduced by NCX 320 was  signiﬁcantly reverted by the soluble guanylate cyclase inhib
20-treated mice and 2.43 ± 0.13 M and 25.9 ± 2.3 M,  respec-
ively, for control mice).
.2.2. Effect of NCX 320 on the amelioration of dystrophic muscle
unction and structure in ˛-SG null mice
To study the therapeutic effect of NCX 320 in muscular dystro-
hy, we relied on -SG null mice, in which the progressive muscle
egeneration with general impairment of locomotor function is
evere and resembles the one observed in human muscular dystro-
hy [18]. We  evaluated the muscle functional activity by analysing
-SG null mice performance in both the free wheel (voluntary activ-
ty capacity) and the treadmill (resistance to forced exercise) tests
fter 8 months of drug treatment. NCX 320-treated animals showed
igniﬁcant amelioration in both tests when compared to control
-SG null mice treated with the standard diet. Conversely, ibupro-
en alone induced a modest increase of voluntary activity and was
ompletely ineffective in ameliorating resistance to forced exercise
Fig. 3A and B).
To investigate the mechanism of this effect, we  analysed skeletal
uscle damage by evaluating serum CK levels, a hallmark of muscle
amage, as well as ﬁbre degeneration and inﬂammatory reactions
t the level of the diaphragm that, as involuntary muscle, is one of
he most damaged in skeletal muscle dystrophy.
NCX 320 treatment signiﬁcantly reduced CK activity (by 48%,
0% and 41% at 2, 3 and 4 months of age respectively, p < 0.05), an
ffect signiﬁcant greater than that observed with ibuprofen alone
Fig. 4A).
Evaluation of H&E-stained sections revealed a signiﬁcantly
ower number of necrotic ﬁbres (Fig. 4B and C) in diaphragm
uscles from animals receiving NCX 320 for 8 months (2.9 ± 0.6
bres/mm2) compared to control, -SG null mice treated with
he standard diet (10.7 ± 2.7 ﬁbres/mm2). Moreover, NCX 320nhibition was estimated from the amount of prostaglandin E2 (PGE2) production.
uares) on methoxamine pre-contracted rabbit aortic rings. The vasodilating effect
DQ (open triangle). Data are expressed as mean ± SEM (n = 3). *p < 0.05 vs ibuprofen.
decreased the accumulation of extracellular scar tissue as revealed
by blue in the Masson trichrome staining (Fig. 4D). On the contrary,
ibuprofen failed to signiﬁcantly reduce necrotic ﬁbres at 8 months
of age in diaphragm muscles (Fig. 4B).
In addition, animals treated with NCX 320 showed a reduced
inﬂammatory reaction compared to the control group as judged by
a signiﬁcant decrease by 36% of inﬂammatory inﬁltrates observed
after H&E staining (Fig. 5A). NCX 320 inhibited the expression of the
pro-inﬂammatory cytokines TGF-, MIP-1 and MCP-1, measured
in tibialis anterior muscle homogenates (Fig. 5B). These results were
similar to those observed with ibuprofen (although it also reduced
TNF- activity), consistent with the NSAID activity of NCX 320.
3.2.3. NCX 320 induces preservation of muscle regeneration
capacity
The ability of muscle myogenic precursor cells to proliferate and
fuse to existing myoﬁbres or to generate new myoﬁbres is the key
event responsible for muscle repair after damage. In DMD  and -
SG null mice, this ability is signiﬁcantly decreased because of the
exhaustion of the myogenic precursor pool due to excessive repair
[12].
We  analysed sections of muscles isolated from mice after
8 months of treatment with NCX 320 or ibuprofen to measure
number of centronucleated/regenerating ﬁbres. Analysis of both
diaphragm and tibialis anterior showed a signiﬁcantly increased
number of newly-formed ﬁbres in the muscles of animals treated
with NCX 320 with respect to control -SG null mice while ibupro-
fen treatment was ineffective (Fig. 6A).We also isolated the myogenic precursor cells from these
muscles, analysed their number by ﬂow cytometry based on
co-expression of the markers CD34 and 7-integrin, and evalu-
ated their ability to differentiate in vitro, a good proxy for their
214 C. Sciorati et al. / Pharmacological Research 64 (2011) 210– 217
Fig. 3. NCX 320 improves muscle function in -SG null mice. (A) Free wheel running to test spontaneous movement and (B) treadmill test to measure resistance to fatigue
were  performed in -SG null mice treated for 8 months with ibuprofen or NCX 320 incorporated into the diet. Animals receiving the same diet without any drug were used
as  control. Data are expressed as mean ± SEM (n = 10). *p < 0.05 vs control animals and #p < 0.05 vs ibuprofen-treated animals.
Fig. 4. NCX 320 reduces skeletal muscle damage in -SG null mice. (A) CK serum levels analysed in mice from 2nd to 4th month of age; (B) number of necrotic ﬁbres quantiﬁed
in  sections of diaphragm muscles after 8 months of treatment ibuprofen or NCX 320 incorporated into the diet. Animals receiving the same diet without any drug were used
as  control. Data are expressed as mean ± SEM (n = 10). *p < 0.05 vs control animals and #p < 0.05 vs ibuprofen-treated animals. (C) and (D) Representative images of one out
of  10 reproducible experiments for H&E and the Masson trichrome staining respectively; scale bars = 100 mm.
C. Sciorati et al. / Pharmacological Research 64 (2011) 210– 217 215
Fig. 5. NCX 320 reduces skeletal muscle inﬂammation in -SG null mice. (A) Number of inﬂammatory inﬁltrates in diaphragm muscles; (B) levels of MCP-1, MIP-1 and TGF-
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egenerative potential [20]. Unlike ibuprofen, NCX 320 increased
igniﬁcantly the number of myogenic precursor cells (Fig. 6B) as
ell as their ability to express the differentiation markers myo-
enin and myosin heavy chain after 1 week of differentiation
Fig. 6C and D).
. Discussion
The pharmacological approaches to human muscular dystro-
hies used in the clinic today are still based on glucocorticoids
dministration, usually prednisolone or deﬂazacort, administered
ccording to various protocols, that delay the disease progression
owever only temporarily and in the presence of severe side effects
38]. Several alternative experimental pharmacological strategies
re being proposed, including administration of calcium antago-
ists and antioxidants, protease inhibitors, compounds that correct
ystrophin gene expression, modulate muscle growth, or stabilise
he link between cytoskeleton and extracellular matrix. None of
hese therapies have so far yielded favourable outcomes in clini-
al trials [22]. Other approaches recently applied to dystrophy and
imed at reducing inﬂammatory reaction by monoclonal antibod-
es or genetic techniques seem to be promising, however still far
rom therapeutic application, because they are expensive and in
ome cases target only subsets of patients [39,40].
In this study, we have characterised NCX 320, a member of
INODs, a class of compounds designed to provide the anti-
nﬂammatory and analgesic efﬁcacy of NSAIDs with additional
eneﬁcial effects due to NO donation.
In particular, we have found that NCX 320 retains the same
nti-inﬂammatory effect of ibuprofen while releasing NO, and such
O donation endows it with signiﬁcant and persistent therapeu-reated for 4 months with ibuprofen or NCX 320 incorporated into the diet. Animals
ean ± SEM (n = 5). *p < 0.05 vs control animals and #p < 0.05 vs ibuprofen-treated
tic effects in the -SG null mouse model of dystrophy, preserving
muscle function, reducing muscle damage and maintaining mus-
cle regeneration capacity. Indeed, those beneﬁcial effects have not
been observed with ibuprofen alone which was effective only in
reducing inﬂammatory reaction.
The beneﬁcial effects of NO on muscle function are well known
and the mechanisms of its action well understood [3].  Approaches
with NO-donors or l-arginine are indeed known to yield ameliora-
tion of the mdx  dystrophic phenotype. However, these compounds
have no therapeutic potential since they yield only transient
effects and seldom have been shown to induce functional recovery
[21,41–45].
A step forward in terms of the use of NO for the therapy of mus-
cular dystrophy came with CINODs. The clear advantage of these
compounds with respect to the classic NO donors is a sustained
release of low concentrations of NO, and its combination with an
anti-inﬂammatory activity [25]. Indeed, a recent study by our group
showed that another CINOD, the NO-donating ﬂurbiprofen HCT
1026, was effective in slowing muscle dystrophy and that, at least in
animal models, it was  superior to the glucocorticoid prednisolone
[18]. However, ﬂurbiprofen produces severe gastrointestinal dam-
age which makes it unsuitable for long-term treatment, especially
in paediatric patients [46]. Therefore, we  have focused on NCX 320
because it is based on ibuprofen, whose proﬁle of safety and tolera-
bility is well established and consequently is accepted for paediatric
use [47]. NCX 320 is indeed cleaved to its active metabolites ibupro-
fen and NO and shows the same efﬁcacy of ibuprofen in COX-1 and
COX-2 inhibition while donating bioactive NO, as demonstrated by
its ability to induce NO/cGMP dependent vasodilation.
The results obtained in the muscular dystrophy model are sig-
niﬁcant. The administration of NCX 320 in the -SG null model of
dystrophy for 8 months reduced muscle damage through the multi-
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Fig. 6. NCX 320 increases muscle regeneration, myogenic precursor cells and regenerative potential. (A) Number of centronucleated-regenerating ﬁbres quantiﬁed in
sections  of diaphragm and tibialis anterior muscles; (B) number of CD34/7 integrin-positive cells isolated from tibialis anterior muscles was measured by ﬂow cytometry;
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tC)  expression of the differentiation markers myogenin (Myog) and myosin heavy c
reated  for 8 months with ibuprofen or NCX 320 incorporated into the diet. Anima
ean  ± SEM (n = 10). *p < 0.05 vs control animals and #p < 0.05 vs ibuprofen-treated
le beneﬁcial effects of NO supply and the anti-inﬂammatory action
f ibuprofen. The ibuprofen moiety limited the generation of pro-
nﬂammatory cytokines and the inﬁltration of inﬂammatory cells,
ossibly in synergy with NO generation [48]. Conversely to other
herapeutic approaches, NCX 320 demonstrated a persistent and
eneﬁcial effect in dystrophic mice in the absence of toxic side
ffects.
It is also important to note that the drug was  administered
tarting from weaning until 10 months of age thus initiating when
nimals show the ﬁrst clear signs of pathology [49]. These signs
re consistent with those observed in dystrophic patients at the
ime of diagnosis, which occurs usually between 2 and 6 years of
ge when they develop delay in talking and walking [50]. Thus,
he drug regimen we applied in the mouse model translates rea-
onably well into humans initiating a therapy at the time of
iagnosis.
The important beneﬁcial effects of combining the properties of
O with those of anti-inﬂammatory drugs have been further con-
rmed by our recent study where the combination of the NO donor
sosorbide dinitrate (ISDN) and ibuprofen showed better therapeu-
ic effects than ISDN or ibuprofen alone in the -SG-null mouse
odel [18]. However, an impressive effect of NCX 320 which was
ot observed to such marked efﬁcacy with the combination ISDN
lus ibuprofen was the capacity to preserve satellite cell number
nd function, an important action in therapeutic perspective. Con-
equently, NCX 320 showed a better resistance to fatigue compared
o the combination.
For all the reasons mentioned above we think that NCX 320
nd other compounds in the same class are an attractive promising
herapy for patients affected by muscular dystrophies.MHC) in isolated myogenic precursor cells. All parameters were evaluated in mice
iving the same diet without any drug were used as control. Data are expressed as
ls. (D) Representative images of the immunoblotting experiments.
5.  Conclusion
NCX 320 showed signiﬁcant and persistent therapeutic effects
preserving muscle function, reducing necrosis of ﬁbres and
inﬂammatory reaction and maintaining regeneration capacity of
muscle. These data further conﬁrm that NO donation together
with anti-inﬂammatory activity improves pathological markers
and locomotor function in a reference model. Given the well-
established and wide use of ibuprofen, these ﬁndings indicate a
path forward for the development of new potential effective agent
for treatment of muscular dystrophy.
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